Best Railroad Stocks To Own Right Now

Best Railroad Stocks To Own Right Now: Echo Therapeutics Inc (ECTE)

Echo Therapeutics, Inc. (Echo), incorporated on September 10, 2007, is a transdermal medical device company. The Company is developing Prelude SkinPrep System (Prelude) as a technology to allow for painless and skin permeation that enable both analyte extraction and needle-free drug delivery. The Company is developing its Symphony CGM System (Symphony) as a non-invasive, wireless continuous glucose monitoring (CGM) system for use in hospital critical care units and for people with diabetes. The Prelude SkinPrep System (Prelude), a component of its Symphony CGM System, allows for skin permeation that enables extraction of analytes such as glucose. Prelude's platform skin preparation technology also allows for needle-free, transdermal drug delivery.

Symphony CGM System

The Symphony CGM System incorporates a Prelude skin preparation device, transdermal sensor, wireless transmitter and data display monitor. When the electro-chemical glucose sensor i s placed on the prepared site, it uses glucose oxidase to generate a continuous current that is proportional to the concentration of blood glucose in the vessels beneath the epidermis. The signals are then wirelessly transmitted to a remote monitor. The monitor, calibrated periodically with a reference blood glucose measurement, converts the data to a glucose measurement based on the reference value. The monitor displays glucose readings and also contains customizable early-warning alarms for hypo- or hyperglycemia.

Prelude SkinPrep System

The Company is developing Prelude as a transdermal skin preparation device for Symphony to improve the access to the interstitial fluids and the flow of molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. Prelude incorporates the Company's skin abrasion co! ntrol technology into a hand-held device used to prepare a small area of the skin. The non-invasive sensor is applied to this prepared area in order to measure the in! terstitial glucose levels.

Specialty Pharmaceuticals

The Company's specialty pharmaceuticals pipeline is based on itsAzone transdermal drug reformulation technology. AzoneTS is a nontoxic, nonirritating skin penetration that is intended to enable topical application of food and drug administration (FDA) -approved drugs, including pharmaceutical products that previously could only be administered systemically. Its advanced drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide, medium potency corticosteroid approved by the FDA for treatment of corticosteroid-responsive dermatoses. AzoneTS increases lipid membrane fluidity in the stratum corneum layer of the skin, thereby decreasing resistance to topically applied therapeutics.

The Company competes with Roche, Johnson & Johnson, Bayer, Abbott Laboratories , DexCom, Inc., Medtronic, Inc., Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Medtronic, Gl ysure, Glumetrics Inc., Maquet and A. Menarini Diagnostics S.r.l.

Advisors' Opinion:

• [By Bryan Murphy]

  Truth be told, Echo Therapeutics Inc. (NASDAQ:ECTE) doesn't look like a particularly impressive stock right now. At $2.92 per share, ECTE is just trading right around where it was a few days ago, not to mention a few weeks ago. And, without any real "news" from the company in months, it's tough to think the market's going to be getting excited about the stock anytime soon. When you take a closer look at Echo Therapeutics though, a few subtle-but-compelling clues start to appear.

• [By Roberto Pedone]

  Another under-$10 health care player that's quickly moving within range of triggering a major breakout trade is Echo Therapeutics (ECTE), which is a transdermal medical device company with skin permeation technolo! gy. This ! stock has been destroyed by the bears so far in 2013, with shares off huge by 70%.

  If you take a look at the chart for Echo Therapeutics, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of $2.14 to its intraday high of $3.06 a share. During that uptrend, shares of ECTE have been consistently making higher lows and higher highs, which is bullish technical price action. That move has pushed shares of ECTE back above its 50-day moving average at $2.65 a share, and it's just starting to push ECTE into breakout territory, since the stock has cleared some key near-term overhead resistance levels at $2.98 to $2.99 a share. That move is quickly pushing shares of ECTE within range of triggering an even bigger breakout trade.

  Market players should now look for long-biased trades in ECTE if it manages to break out above some major near-term overhead resistance at $3.30 a share with high volume. Look for a sustained move or close above that level with volume that registers near or above its three-month average volume of 211,103 shares. If that breakout triggers soon, then ECTE will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.50 a share, or possibly even $5 to $6 a share.

  Traders can look to buy ECTE off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $2.65 a share, or right below more near-term support at $2.50 a share. One can also buy ECTE off strength once it clears $3.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-railroad-stocks-to-own-right-now-2.html